Facial Erythema Treatment Market

Facial Erythema Treatment Market Outlook (2022 to 2032)

The global facial erythema treatment market is expected to be valued at USD 299 million by 2032, up from USD 173.3 million in 2022, growing at a 5.1% CAGR during the forecast period.

The growing patient population, large pipeline drugs, and other factors are likely to drive up demand for facial erythema treatment. However, strict government regulations governing drug product approvals are expected to stymie global market growth.

On the contrary, increasing Research and Development activities and advancements in drug products are projected to provide manufacturers with more opportunities.

Clinic applications are expected to grow significantly during the forecast period due to rising practitioner awareness of early detection and efficient treatments that do not require any kind of invasive procedures or surgeries. Patients with mild cases, or those who are uncomfortable visiting healthcare facilities for treatment, are more likely to prefer at-home care.

Attributes	Details
Facial Erythema Treatment Market Size (2022)	USD 173.3 Million
Facial Erythema Treatment Market Size (2032)	USD 299 Million
Facial Erythema Treatment Market CAGR	5.1%

Demand for Minimally Invasive Procedures and Other Factors Likely to Drive the Facial Erythema Treatment Market

The steadily rising use of alcohol, cigarettes, and other narcotics may result in a variety of skin diseases. Furthermore, changing climatic conditions, the introduction of new products, and allergic reactions all contribute to skin abnormalities such as rosacea, which increases the use of facial erythema treatment.

The demand for minimally invasive procedures is increasing due to advantages such as shorter recovery time and less pain post-procedure. Furthermore, people are becoming increasingly aware of the various types of facial erythema treatment options available on the market. These are important factors that are expected to drive market growth.

People have a growing desire to improve their appearance, especially if they have skin conditions like perioral dermatitis, systemic illness, or rosacea. These, along with the need for skin cancer protection, are expected to significantly drive demand for facial erythema treatment.

Obstructions & Future Prospects of Facial Erythema Treatment Reshaping the Market

Certain medications used during the treatment of facial erythema may cause side effects. Antibiotics, for example, can cause bloating, abdominal pain, loss of appetite, and other side effects. This factor is likely to limit the use of this type of treatment.

In contrast, due to varying utilization demands, key manufacturers are primarily focusing on new product solutions for specific applications. During the forecast period, these factors are expected to generate creative opportunities for market share and increase demand for facial erythema treatment.

How will the North America & Europe Facial Erythema Treatment Markets Grow?

North America is the most dominant facial erythema treatment market, accounting for 42% of total revenue. This is due to the majority of the population having fair skin and being prone to skin problems, resulting in the treatment's early adoption.

Climate changes, as well as population lifestyle changes, contribute to a variety of skin diseases. Furthermore, there has been an increase in skin treatment awareness in this region. These factors are likely to sustain the region's growing demand for facial erythema treatment and boost the global market growth.

The US government spends a lot of money on pharmaceuticals and medical devices every year, and they raise awareness in society. Furthermore, the business of the facial erythema treatment market is endorsed by the collaboration of multiple international companies with a slew of major hospital chains.

With revenue of 33.7%, Europe is the second-largest facial erythema treatment market. This is due to rising alcohol consumption and extensive research and development activities in the region.

Unveiling the Start-up Economy Contributing to the Facial Erythema Treatment Market Growth

Most cases of facial erythema, such as rosacea, have no known cause or treatment. It does, however, cause significant discomfort to those who suffer from these skin conditions. In many cases, it causes extreme embarrassment, anxiety, and depression. As a result, start-up companies are taking these issues into account and devising solutions to reduce their prevalence, fueling the growth of the facial erythema treatment market.

Praxis Biotechnology

Dr. Wladis and Dr. Adam founded Praxis Biotechnology in response to a lack of rosacea treatment options. Praxis Biotechnology is based at Albany Medical College. Praxis Biotechnology was recently awarded USD 50,000 after winning FuzeHub's commercialization competition. This medication, according to the non-profit, could benefit millions of people.

Legit Health

Legit Health is a Spanish start-up that offers a skin diagnostic tool. The startup's software employs artificial intelligence to classify 139 skin pathologies, with a focus on the detection of seven of these, including acne, rosacea, and dermatitis. The software's algorithms automatically fill in most medical grading systems for the seven skin conditions.

Dermatica

The team at this UK start-up develops an evidence-based treatment and delivers it monthly. The web-based platform of the start-up assists patients in developing relationships with medical professionals and seeking expert assistance when necessary. The company also develops treatments for acne, facial erythema, anti-aging, pigmentation, and melasma.

Competitive Landscape of Facial Erythema Treatment Transforming the Outlook of the Market

Due to the involvement of several established players, the market share for facial erythema treatment is highly competitive. These players are focusing on expanding their presence through acquisitions, expansions, product approvals, and launches in order to capitalize on market growth opportunities.

Latest Developments:

• Eucrisa (crisaborole) ointment was approved by the FDA in June 2016 to treat mild to moderate atopic dermatitis. It is an eczema treatment for patients aged two and up that was developed by Anacor Pharmaceuticals, which Pfizer purchased for USD 4.5 billion. The condition causes red, scaly, crusted bumps that are extremely itchy.
• Arcutis launched Zoryve in the United States in July 2022, shortly after acquiring plaque psoriasis. Arcutis revealed late-stage roflumilast foam data in seborrheic dermatitis, a chronic inflammatory skin disease in which the company is testing its drug in adults and children aged nine and up with the moderate-to-severe disease.
• Galderma S.A. received European Commission marketing authorization for its Mirvaso gel in February 2014.

Other Market Participants of the Facial Erythema Treatment Market:

• Novartis International AG
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• Valeant Pharmaceuticals International Inc.
• Bausch Health Companies Inc.
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Enzon Pharmaceuticals

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 5.1% from 2022 to 2032
The base year for estimation	2021
Historical data	2015 to 2020
Forecast period	2022 to 2032
Quantitative units	Revenue in USD million, volume in kilotons, and CAGR from 2022 to 2032
Report Coverage	Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,
Segments Covered	Drug Type, Disease Type, Distribution Channel, and Region.
Regional scope	North America; Western Europe; Eastern Europe; Middle East; Africa, ASEAN; South Asia; Rest of Asia; Australia; and New Zealand
Country scope	United States of America, Canada; Mexico, Germany, United Kingdom, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa
Key companies profiled	Anacor Pharmaceuticals Inc.; Astellas Pharma Inc.; Galderma S.A.; Meda Pharmaceuticals; Pfizer Inc.; Novartis International AG; Regeneron Pharmaceuticals Inc.; Sanofi S.A.; Valeant Pharmaceuticals International Inc.; Bausch Health Companies Inc.; GlaxoSmithKline plc; Merck & Co. Inc.; Enzon Pharmaceuticals; etc.
Customization scope	Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs.

Key Segments Profiled in the Facial Erythema Treatment Market Survey 

By Drug Type:

• Emollients
• Antihistamines
• Antifungal
• Antibiotics
• Corticosteroids
• Calcineurin Inhibitors

By Disease Type:

• Erythematotelangiectatic (ETR)
• Papulopustular (PPR)
• Phymatous
• Ocular

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Asia Pacific
• Middle East and Africa
• Europe

Frequently Asked Questions

How much CAGR can be approximated for the Facial Erythema Treatment Market?

The facial erythema treatment market is likely to accumulate a CAGR of 5.1%, during the forecast period.

What is the Leading Regional Market of Facial Erythema Treatment?

North America is the leading facial erythema treatment market with revenue of 42%.

What will be the Size of the Facial Erythema Treatment Market by 2032?

By 2032, the facial erythema treatment market is likely to grow to a valuation of USD 299 Million.